Vivos Therapeutics (VVOS) Free Cash Flow Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 29.12% |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -53.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.85% |
| Dec 31, 2025 | -162.09% |
| Sep 30, 2025 | 5.98% |
| Jun 30, 2025 | -37.55% |
| Mar 31, 2025 | -46.91% |
| Dec 31, 2024 | -47.02% |
| Sep 30, 2024 | -48.24% |
| Jun 30, 2024 | 6.78% |
| Mar 31, 2024 | 24.87% |
| Dec 31, 2023 | 33.73% |
| Sep 30, 2023 | 50.77% |
| Jun 30, 2023 | 34.68% |
| Mar 31, 2023 | 42.93% |
| Dec 31, 2022 | -43.69% |
| Sep 30, 2022 | -34.71% |
| Jun 30, 2022 | -1.86% |
| Mar 31, 2022 | -49.45% |
| Dec 31, 2021 | 38.30% |
| Sep 30, 2021 | -548.85% |
| Jun 30, 2021 | -422.85% |